Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,653 questions in 194 reviews · Gynaecology and Fertility
current versionsNo studies 531 · 20%Ungraded 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Helium thermal coagulator vs electrodiathermy Quality of life (9 months) – EHP‐30 social support · endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | no estimate extracted | 1 study · 119 participants | Very low |
Helium thermal coagulator vs electrodiathermy Quality of life (9 months) – EHP‐30 self‐image · endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | no estimate extracted | 1 study · 119 participants | Very low |
Helium thermal coagulator vs electrodiathermy Adverse events · endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | no estimate extracted | 1 study · 192 participants | Very low |
Laparoscopic treatment vs diagnostic laparoscopy Overall pain scores unclear measurement instrument (12 months) · women with endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Laparoscopic treatment vs diagnostic laparoscopy Live birth · women with endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | no estimate extracted | NR | No studies |
Laparoscopic treatment vs diagnostic laparoscopy Quality of life EQ‐5D index summary (6 months) · women with endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Laparoscopic treatment vs diagnostic laparoscopy Quality of life SF‐12 mental health component (6 months) · women with endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Laparoscopic treatment vs diagnostic laparoscopy Quality of life SF‐12 physical health component (6 months) · women with endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Laparoscopic treatment vs diagnostic laparoscopy Viable intrauterine pregnancy confirmed by ultrasound · women with endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | OR 1.89 [1.25, 2.86] | 3 studies · 528 participants | Moderate |
Laparoscopic treatment vs diagnostic laparoscopy Pregnancy loss: ectopic pregnancy per pregnancy · women with endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | OR 1.18 [0.1, 13.48] | 1 study · 100 participants | Low |
Laparoscopic treatment vs diagnostic laparoscopy Pregnancy loss: miscarriage per pregnancy · women with endometriosis Laparoscopic surgery for endometriosis (2020) · Cochrane | OR 0.94 [0.35, 2.54] | 2 studies · 112 participants | Low |
UAE/UACE vs systemic MTX Treatment success after initial treatment UAE vs systemic MTX · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | RR 1 [0.9, 1.12] | 1 study · 72 participants | Low |
Suction curettage under hysteroscopy vs under ultrasonography Time to normalize β‐hCG after UAE · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | no estimate extracted | 1 study · 66 participants | Very low |
UAE/UACE vs systemic MTX Complications UAE vs systemic MTX · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | RR 0.47 [0.13, 1.75] | 1 study · 72 participants | Low |
UAE/UACE vs systemic MTX Adverse effects UAE vs systemic MTX · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | RR 1.58 [0.41, 6.11] | 1 study · 72 participants | Low |
UAE/UACE vs systemic MTX Blood loss UAE vs systemic MTX · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | no estimate extracted | 1 study · 72 participants | Moderate |
UAE/UACE vs systemic MTX Time to normalize β‐hCG · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | no estimate extracted | NR | No studies |
Suction curettage under hysteroscopy vs under ultrasonography Treatment success after initial treatment after UAE · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | RR 0.91 [0.81, 1.03] | 1 study · 66 participants | Very low |
Suction curettage under hysteroscopy vs under ultrasonography Complications after UAE · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | RR 4 [0.47, 33.91] | 1 study · 66 participants | Very low |
Suction curettage under hysteroscopy vs under ultrasonography Adverse effects after UAE · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | RR 3.09 [0.12, 78.7] | 1 study · 66 participants | Very low |
Suction curettage under hysteroscopy vs under ultrasonography Blood loss · women with CSP Interventions for non‐tubal ectopic pregnancy (2020) · Cochrane | no estimate extracted | NR | No studies |
LNG‐IUS vs non‐intrauterine progestogen Regression of EH; by length of · endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | OR 2.94 [2.1, 4.13] | 10 studies · 1108 participants | Moderate |
LNG vs no treatment Adverse effects associated with hormones · women with endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
LNG vs no treatment Withdrawal secondary to adverse effects · women with endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
LNG vs no treatment Satisfaction · women with endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
LNG vs no treatment Cost of treatment · women with endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
LNG‐IUS vs non‐intrauterine progestogen Regression of EH; by length of · endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | OR 3.8 [1.75, 8.23] | 1 study · 138 participants | Low |
LNG‐IUS vs non‐intrauterine progestogen Hysterectomy; histologically and non‐histologically indicated · endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | OR 0.26 [0.15, 0.46] | 4 studies · 452 participants | Low |
LNG‐IUS vs non‐intrauterine progestogen Adverse effects associated with hormones:Bleeding/spotting Nausea Weight gain · endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | OR 2.13 [1.33, 3.43] | 3 studies · 428 participants | Very low |
LNG‐IUS vs non‐intrauterine progestogen Withdrawal secondary to adverse effects · endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | OR 0.41 [0.12, 1.35] | 4 studies · 360 participants | Low |
LNG‐IUS vs non‐intrauterine progestogen Satisfaction with treatment · endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | OR 5.28 [2.51, 11.1] | 2 studies · 202 participants | Very low |
LNG vs no treatment Regression of EH ‐ Short · women with endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | OR 78.41 [22.86, 268.97] | 1 study · 190 participants | Low |
LNG vs no treatment Adverse effects associated with LNG‐IUS · women with endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
LNG vs no treatment Hysterectomy · women with endometrial hyperplasia Levonorgestrel‐releasing intrauterine system for endometrial hyperplasia (2020) · Cochrane | no estimate extracted | NR | No studies |
Embryo culture supernatant injection vs no intervention Live birth/ongoing pregnancy · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | OR 1.11 [0.73, 1.7] | 3 studies · 340 participants | Very low |
Embryo culture supernatant vs culture medium injection Clinical pregnancy · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | OR 1.09 [0.48, 2.46] | 1 study · 96 participants | Very low |
Embryo culture supernatant vs culture medium injection Ectopic pregnancy · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | no estimate extracted | NR | No studies |
Embryo culture supernatant vs culture medium injection Multiple pregnancy · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | no estimate extracted | NR | No studies |
Embryo culture supernatant vs culture medium injection Preterm delivery · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | no estimate extracted | NR | No studies |
Embryo culture supernatant vs culture medium injection Foetal abnormalities · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | no estimate extracted | NR | No studies |
Embryo culture supernatant injection vs no intervention Miscarriage · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | OR 0.89 [0.44, 1.78] | 4 studies · 430 participants | Very low |
Embryo culture supernatant injection vs no intervention Clinical pregnancy · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | OR 1.13 [0.8, 1.61] | 5 studies · 526 participants | Very low |
Embryo culture supernatant injection vs no intervention Ectopic pregnancy · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | OR 0.32 [0.01, 8.24] | 2 studies · 250 participants | Very low |
Embryo culture supernatant injection vs no intervention Multiple pregnancy · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | OR 0.7 [0.26, 1.83] | 2 studies · 150 participants | Very low |
Embryo culture supernatant injection vs no intervention Preterm delivery · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | OR 0.63 [0.17, 2.42] | 1 study · 90 participants | Very low |
Embryo culture supernatant injection vs no intervention Foetal abnormalities · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | OR 3.1 [0.12, 79.23] | 1 study · 60 participants | Low |
Embryo culture supernatant vs culture medium injection Live birth/ongoing pregnancy · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | no estimate extracted | NR | No studies |
Embryo culture supernatant vs culture medium injection Miscarriage · Subfertile women undergoing assisted reproduction Endometrial injection of embryo culture supernatant for subfertile women in assisted reproduction (2020) · Cochrane | no estimate extracted | NR | No studies |
G‐CSF vs no treatment or placebo Ongoing pregnancy rate per woman randomised · subfertile women undergoing assisted reproduction Granulocyte‐colony stimulating factor administration for subfertile women undergoing assisted reproduction (2020) · Cochrane | RR 1.62 [0.86, 3.08] | 1 study · 150 participants | Very low |
G‐CSF vs no treatment or placebo Miscarriage rate per woman randomised · subfertile women undergoing assisted reproduction Granulocyte‐colony stimulating factor administration for subfertile women undergoing assisted reproduction (2020) · Cochrane | Peto OR 0.4 [0.09, 1.77] | 2 studies · 291 participants | Very low |